Switch theme
Sign up to access all valuation multiples
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
2015
1.1K+
LTM Revenue $165M
LTM EBITDA -$78.6M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InnoCare Pharma has a last 12-month revenue of $165M and a last 12-month EBITDA of -$78.6M.
In the most recent fiscal year, InnoCare Pharma achieved revenue of $95.0M and an EBITDA of -$66.4M.
InnoCare Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InnoCare Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $80.4M | $95.0M | XXX | XXX | XXX |
| Gross Profit | $126M | $62.0M | XXX | XXX | XXX |
| Gross Margin | 156% | 65% | XXX | XXX | XXX |
| EBITDA | -$104M | -$66.4M | XXX | XXX | XXX |
| EBITDA Margin | -129% | -70% | XXX | XXX | XXX |
| Net Profit | -$8.3M | -$114M | XXX | XXX | XXX |
| Net Margin | -10% | -120% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, InnoCare Pharma's stock price is HKD 10 (or $1).
InnoCare Pharma has current market cap of HKD 18.4B (or $2.4B), and EV of HKD 12.0B (or $1.5B).
See InnoCare Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $2.4B | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, InnoCare Pharma has market cap of $2.4B and EV of $1.5B.
InnoCare Pharma's trades at 10.0x LTM EV/Revenue multiple, and -21.0x LTM EBITDA.
Analysts estimate InnoCare Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for InnoCare Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 16.2x | XXX | XXX | XXX |
| EV/EBITDA | -23.1x | XXX | XXX | XXX |
| P/E | -29.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpInnoCare Pharma's NTM/LTM revenue growth is 35%
InnoCare Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, InnoCare Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate InnoCare Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for InnoCare Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -70% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -36% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -35% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 102% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 171% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InnoCare Pharma acquired XXX companies to date.
Last acquisition by InnoCare Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . InnoCare Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was InnoCare Pharma founded? | InnoCare Pharma was founded in 2015. |
| Where is InnoCare Pharma headquartered? | InnoCare Pharma is headquartered in Hong Kong. |
| How many employees does InnoCare Pharma have? | As of today, InnoCare Pharma has 1.1K+ employees. |
| Who is the CEO of InnoCare Pharma? | InnoCare Pharma's CEO is Dr. Jisong Cui, PhD. |
| Is InnoCare Pharma publicy listed? | Yes, InnoCare Pharma is a public company listed on HKG. |
| What is the stock symbol of InnoCare Pharma? | InnoCare Pharma trades under 09969 ticker. |
| When did InnoCare Pharma go public? | InnoCare Pharma went public in 2020. |
| Who are competitors of InnoCare Pharma? | Similar companies to InnoCare Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of InnoCare Pharma? | InnoCare Pharma's current market cap is $2.4B |
| What is the current revenue of InnoCare Pharma? | InnoCare Pharma's last 12-month revenue is $165M. |
| What is the current EBITDA of InnoCare Pharma? | InnoCare Pharma's last 12-month EBITDA is -$78.6M. |
| What is the current EV/Revenue multiple of InnoCare Pharma? | Current revenue multiple of InnoCare Pharma is 10.0x. |
| What is the current EV/EBITDA multiple of InnoCare Pharma? | Current EBITDA multiple of InnoCare Pharma is -21.0x. |
| What is the current revenue growth of InnoCare Pharma? | InnoCare Pharma revenue growth between 2023 and 2024 was 18%. |
| Is InnoCare Pharma profitable? | Yes, InnoCare Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
